27/05/2026
Nemolizumab is a targeted biologic therapy used in dermatology to treat conditions driven by severe itch, particularly moderate-to-severe atopic dermatitis and prurigo nodularis (pictured). It works by blocking the IL-31 receptor, a key pathway involved in chronic itch and skin inflammation, helping reduce pruritus and improve skin symptoms.
Read more here: https://dermnetnz.org/topics/nemolizumab